MSD Korea announced on the 11th that a combination therapy of anti-PD-1 immuno-cancer drug Keytruda (Pembrolizumab) and Lenvima (Lenvatinib) has been approved by the MFDS as the primary treatment for advanced new cell carcinoma.

Combination therapy of Keytruda and Lenvima in renal cell cancer treatment recorded 23.9 months of mPFS and improved OS in a phase 3 clinical CLEAR study. Studies have shown that Keytruda-Lenvima reduced the risk of disease progression or death by 61% (HR=0.39) compared to Sunitinib. The risk of death was reduced by 34% (HR=0.66). The overall survival period did not reach the median value. Keytruda-Lenvima's objective response rate (ORR) was 71%, significantly higher than that o